Welcome!

News Feed Item

Alchemia Announces Half-Year Results for Period Ended 31 December 2013

BRISBANE, AUSTRALIA -- (Marketwired) -- 02/18/14 -- Alchemia Limited, (ASX: ACL) a drug discovery and development company, is pleased to announce its half year results for the six months ended 31 December 2013.

Highlights for the first half of the financial year include:

  • Total revenue of $5.0 million for the six months ended 31 December 2013
  • $4.7 million in fondaparinux profit share payments for the period
  • Cash receipts of $8.8 million in R&D tax incentives received in period due to R&D spend incurred in the previous financial year
  • Cash balance of $16.4 million as at 31 December 2013.

Generic fondaparinux

For the half year ended 31 December 2013, the Company reports that under the collaboration, development and marketing agreement with Alchemia's commercial partner, Dr Reddy's Laboratories, profits of $4.7 million were payable to Alchemia Limited. This amount is in lieu of sales made by Dr Reddy's Laboratories of Alchemia's fondaparinux in the US and takes into account the payment of $1.1 million to Dr Reddy's Laboratories by Alchemia Limited for agreed activities to improve yields and cost of goods.

Alchemia Oncology
Over the six-month period, Alchemia continued to treat patients in the Company's pivotal Phase III clinical trial of HA-Irinotecan in metastatic colorectal cancer (mCRC). The primary objective of the Phase III study is to demonstrate that HA-Irinotecan is superior to Irinotecan in its effect on Progression Free Survival (PFS). The primary endpoint of this trial will be reached when 350 patients have experienced disease progression or death.

The trial has recruited patients with 2nd or 3rd line metastatic colorectal cancer (mCRC) where patients are randomised to receive either FOLFIRI (a combination of the cancer drugs 5-FU, leucovorin and irinotecan) or FOLF(HA)-Iri in which irinotecan is replaced with Alchemia's proprietary formulation, HA-Irinotecan.

A brief study outline is as follows:

  • 415 second-line metastatic colorectal cancer patients, randomised and double-blinded: neither the patient nor clinician knows which treatment is being administered;
  • Half of patients will receive Alchemia's HA-Irinotecan in combination with 5-fluorouracil and leucovorin (test arm) and half will receive unmodified irinotecan with 5-fluorouracil and leucovorin (control arm);
  • 76 sites in Australia, the UK, Russia, Ukraine, Bulgaria, Poland and Serbia;
  • Primary endpoint of progression-free survival where the statistical assumptions are based on FOLF(HA)-Iri providing a minimum of a six week improvement in PFS compared with the control arm;
  • Primary endpoint assessed after disease progression or death in 350 patients

In addition, Alchemia has initiated an investigator-led Phase II clinical trial of HA-Irinotecan in combination with carboplatin in small cell lung cancer. Currently 27 patients have been enrolled in the study and in October of 2013, interim results were presented at the 15th World Conference of Lung Cancer in Sydney, showing that HA-Irinotecan in combination with carboplatin is safe to administer and that there are early encouraging signs of clinical activity.

Another significant advancement in the clinical development of HA-Irinotecan was achieved in May of 2013 when Alchemia and Merck Serono agreed to collaborate by supporting the initiation of a new investigator-led clinical trial of HA-Irinotecan in combination with Merck Serono's leading therapeutic antibody, Erbitux® (cetuximab), for patients with metastatic colorectal cancer (mCRC). Up to 50 patients who are candidates for second-line treatment of mCRC, will to be enrolled at six to ten sites around Australia with the trial scheduled to run for approximately 24 months. This trial is currently in the organisational stage and recruitment is expected to begin in the first half of calendar year 2014.

Alchemia's oncology programs, including HA-irinotecan, are all based on its proprietary HyACT® technology for targeting cancer therapies to tumours. The HyACT drug delivery platform presents the Company with multiple product opportunities as we believe that HyACT may be able to improve the delivery of a range of chemotherapeutic agents to cancer cells and boost drug efficacy without increasing side effects. The technology has applications ranging from small molecule cytotoxics to much larger biologics, such as monoclonal antibodies. Due to the versatility of this platform, Alchemia is seeking to further deploy this technology to improve the treatment and survival of patients with cancer.

Drug Discovery

Alchemia's VAST technology utilises pyranose as a scaffold to generate novel molecules that are more diverse and complex in shape than the typical compounds used in drug discovery. Using these chemistries the Company has developed an array of compounds it refers to as, "Diversity Scanning Array" (DSA), which represents approximately 14,000 pyranose-based compounds that systematically arrange typical binding groups in a broad range of possible three-dimensional orientations. This array has the ability to identify the shape and functional requirements of molecules that modulate a target.

On the basis of this technology, Alchemia established a multi-target drug discovery collaboration with AstraZeneca AB in April of 2013, where Astra Zeneca will apply the technology across a variety of therapeutic areas including oncology, respiratory, cardiovascular, metabolism, infection and neuroscience. This collaboration will exploit the unique shape diversity provided by DSA and versatility offered by VAST to approach difficult therapeutic targets in innovative ways. Following the signing of the agreement, a copy of the DSA has been transferred to AstraZeneca AB and high throughput screening campaigns are ongoing on several targets.

Alchemia has also put in place strong collaborations with the Institute for Molecular Biosciences (University of Queensland) to discover novel inhibitors of selected ion channels and with the Monash Institute for Pharmaceutical Science to discover novel allosteric modulators of the Family B G-protein coupled receptors. These collaborations aim to discover new treatments for pain, chronic obstructive pulmonary disease and type II diabetes. The collaborations are supported by government grants, which help fund specialised biology teams in the respective institutes, fully focussed on the collaborative drug discovery efforts. These types of collaborations maximise the use of the VAST platform in a highly cost efficient manner.

Financials

The Group reported a net loss of $5.5 million for the six months ended 31 December 2013, an improvement from its $5.9 million loss for the six months ended 31 December 2012.

Total income for the period was $5.0 million, a decrease of $4.4 million from the previous period (2013: $9.4 million), during which the Group received $4.5 million R&D tax incentive income.

Operating expenses of $10.7 million were lower than the corresponding period of $15.5 million). The reduction in Administrative and Corporate Costs of $1.9 million was mainly related to the costs associated with the deferment of the demerger and listing of Audeo Oncology, Inc., which was expensed in December of 2012. The reduction in costs associated with conducting the HA-Irinotecan Phase III trial in patients with mCRC of $3.5 million relates to a significant spend in the six months to 31 December 2012 due to the registrational trial.

Over the course of the reporting period, Alchemia has seen a significant net increase in cash balances, (including cash, cash equivalents and term deposits) from $6.1 million as at 31 December 2012 to $16.4 million as at 31 December 2013. Cash balance in the period was boosted by cash receipts of $5.9 million royalty payments from Dr Reddy's and $8.8 million from R&D tax incentives versus operating expenditure of just $11.2 million.

The group acquired capital items totalling $0.2 million during the period, up from $0.1 million in the prior year period.

About Alchemia Limited - www.alchemia.com.au

Alchemia is a drug discovery and development company marketing FDA approved fondaparinux, an injectible antithrombotic in the US, as well as other major markets via partner Dr. Reddy's Laboratories. The Company is also developing a late stage oncology product pipeline with multiple ongoing trials through its proprietary HyACT drug delivery platform, which targets anti-cancer drugs to solid tumours. Lead asset HA-Irinotecan is in a pivotal Phase III clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in two Phase II investigator-led trials, one of which is in collaboration with Merck Serono combining HA-Irinotecan with Erbitux® (cetuximab). Alchemia is also exploring additional small molecule drug discovery targets via an internal discovery platform VAST, based on the Company's deep chemistry expertise. The VAST technology is being developed in collaboration with leading academic institutions and is partnered with AstraZeneca AB.

Erbitux® is a trademark of Merck KGaA.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The security needs of IoT environments require a strong, proven approach to maintain security, trust and privacy in their ecosystem. Assurance and protection of device identity, secure data encryption and authentication are the key security challenges organizations are trying to address when integrating IoT devices. This holds true for IoT applications in a wide range of industries, for example, healthcare, consumer devices, and manufacturing. In his session at @ThingsExpo, Lancen LaChance, vic...
Big Data, cloud, analytics, contextual information, wearable tech, sensors, mobility, and WebRTC: together, these advances have created a perfect storm of technologies that are disrupting and transforming classic communications models and ecosystems. In his session at @ThingsExpo, Erik Perotti, Senior Manager of New Ventures on Plantronics’ Innovation team, provided an overview of this technological shift, including associated business and consumer communications impacts, and opportunities it m...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
In their general session at 16th Cloud Expo, Michael Piccininni, Global Account Manager - Cloud SP at EMC Corporation, and Mike Dietze, Regional Director at Windstream Hosted Solutions, reviewed next generation cloud services, including the Windstream-EMC Tier Storage solutions, and discussed how to increase efficiencies, improve service delivery and enhance corporate cloud solution development. Michael Piccininni is Global Account Manager – Cloud SP at EMC Corporation. He has been engaged in t...
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
WebRTC is bringing significant change to the communications landscape that will bridge the worlds of web and telephony, making the Internet the new standard for communications. Cloud9 took the road less traveled and used WebRTC to create a downloadable enterprise-grade communications platform that is changing the communication dynamic in the financial sector. In his session at @ThingsExpo, Leo Papadopoulos, CTO of Cloud9, discussed the importance of WebRTC and how it enables companies to focus o...
Big Data engines are powering a lot of service businesses right now. Data is collected from users from wearable technologies, web behaviors, purchase behavior as well as several arbitrary data points we’d never think of. The demand for faster and bigger engines to crunch and serve up the data to services is growing exponentially. You see a LOT of correlation between “Cloud” and “Big Data” but on Big Data and “Hybrid,” where hybrid hosting is the sanest approach to the Big Data Infrastructure pro...
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Hardware virtualization and cloud computing allowed us to increase resource utilization and increase our flexibility to respond to business demand. Docker Containers are the next quantum leap - Are they?! Databases always represented an additional set of challenges unique to running workloads requiring a maximum of I/O, network, CPU resources combined with data locality.
In his General Session at DevOps Summit, Asaf Yigal, Co-Founder & VP of Product at Logz.io, will explore the value of Kibana 4 for log analysis and will give a real live, hands-on tutorial on how to set up Kibana 4 and get the most out of Apache log files. He will examine three use cases: IT operations, business intelligence, and security and compliance. This is a hands-on session that will require participants to bring their own laptops, and we will provide the rest.
"We're bringing out a new application monitoring system to the DevOps space. It manages large enterprise applications that are distributed throughout a node in many enterprises and we manage them as one collective," explained Kevin Barnes, President of eCube Systems, in this SYS-CON.tv interview at DevOps at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
In his General Session at 16th Cloud Expo, David Shacochis, host of The Hybrid IT Files podcast and Vice President at CenturyLink, investigated three key trends of the “gigabit economy" though the story of a Fortune 500 communications company in transformation. Narrating how multi-modal hybrid IT, service automation, and agile delivery all intersect, he will cover the role of storytelling and empathy in achieving strategic alignment between the enterprise and its information technology.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists peeled away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud enviro...
With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo 2016 in New York. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be! Internet of @ThingsExpo, taking place June 6-8, 2017, at the Javits Center in New York City, New York, is co-located with 20th Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry p...
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...